In this article, we will list the 5 Tiny Stocks That Are On Fire Right Now. Please visit 10 Tiny Stocks That Are On Fire Right Now to see the extended list and the methodology behind it.
5. Silvaco Group Inc. (NASDAQ:SVCO)
Year-to-Date Performance: 157.41%
Silvaco Group Inc. (NASDAQ:SVCO) is one of the tiny stocks that are on fire right now. On April 20, Silvaco Group entered into a strategic partnership with Taiwan’s Industrial Technology Research Institute/ITRI to support the development of next-gen microcontroller units/MCUs. Under this agreement, ITRI will deploy Silvaco’s SmartSpice circuit simulation platform within its Nankang IC Design Incubation Center.
This integration is designed to provide startups with the high-precision verification and simulation tools necessary to accelerate development cycles for analog, mixed-signal, and RF circuit designs. The collaboration focuses on fostering semiconductor innovation by lowering the barrier to entry for emerging companies. By providing access to industry-standard EDA/Electronic Design Automation tools, Silvaco, and ITRI aim to streamline the transition from initial design to market-ready MCU solutions.
In addition to the software deployment, both organizations are exploring further opportunities to expand their support for the semiconductor ecosystem. This partnership aligns with Silvaco Group Inc.’s (NASDAQ:SVCO) broader strategy of providing AI-enabled TCAD and EDA solutions across high-growth markets such as automotive, IoT, and 5G/6G mobile systems.
Silvaco Group Inc. (NASDAQ:SVCO) provides AI-enabled TCAD, EDA, and SIP solutions for global semiconductor design. Its software enables digital twin modeling and process optimization across diverse markets, including automotive, 5G/6G, and HPC.
4. Sutro Biopharma Inc. (NASDAQ:STRO)
Year-to-Date Performance: 183.15%
Sutro Biopharma Inc. (NASDAQ:STRO) is one of the tiny stocks that are on fire right now. On March 23, Sutro Biopharma reported its full-year 2025 financial results, highlighting a strengthened balance sheet and significant clinical milestones for its antibody-drug conjugate/ADC platform. The company ended 2025 with $141.4 million in cash and marketable securities, which, when combined with a recent $110 million capital raise, extends its cash runway into at least Q2 2028. This financial stability supports a sharpened focus on advancing both wholly owned and partnered oncology programs.
A major focus for 2026 is the progress of Sutro’s internal pipeline. The company completed dosing for the third cohort in its Phase 1 trial of STRO-004, a potential best-in-class Tissue Factor/TF ADC, with initial clinical data expected in mid-2026. Additionally, Sutro Biopharma Inc. (NASDAQ:STRO) is accelerating the development of STRO-227, its first wholly owned dual-payload program targeting PTK7, with an IND submission now targeted for 2026. The company also expects its ITGB6-targeting ADC, STRO-006, to enter clinical development this year.
Sutro’s collaboration with Astellas Pharma has also reached a key inflection point, with their first partnered dual-payload immunostimulatory ADC entering the clinic. Patient dosing is currently in Q2 2026. A second partnered program also advanced into IND-enabling toxicology studies late last year, further validating Sutro’s site-specific ADC platform through strategic partnerships.
Sutro Biopharma Inc. (NASDAQ:STRO) is a clinical-stage biotechnology company using a proprietary cell-free platform to develop next-gen antibody-drug conjugates/ADCs for cancer. By optimizing antibodies, linkers, and single or dual-payloads, the company aims to improve drug exposure and overcome treatment resistance in oncology markets with significant unmet needs.
3. Syntec Optics Holdings Inc. (NASDAQ:OPTX)
Year-to-Date Performance: 228.15%
Syntec Optics Holdings Inc. (NASDAQ:OPTX) is one of the tiny stocks that are on fire right now. On April 21, Syntec Optics secured a ~$2 million expansion order for integrated micro cameras designed for next-gen, AI-enabled AR systems for the US military. This contract follows the company’s successful execution of ballistic optics projects and marks a move into the sensing layer of defense technology.
The initial deployment serves as a foundation for projected recurring annual orders through 2030, as the US Department of Defense prioritizes equipping soldiers with advanced sensor fusion and computer vision capabilities. The micro cameras are mission-critical components that enable superhuman situational awareness by feeding raw optical data into AI software to create real-time, 3D battlefield maps.
To prevent motion sickness and ensure a stable digital overlay, these optics must meet nanoscale precision tolerances. Syntec’s purpose-built sensors are designed to maintain high fidelity under extreme thermal stress, small form factors, and low-light conditions, reducing latency to near zero. A key driver for this award is Syntec Optics Holdings Inc.’s (NASDAQ:OPTX) vertically integrated, US-based manufacturing footprint. The recent National Defense Authorization Act mandates require critical optical technologies to be manufactured domestically to ensure a secure, sovereign supply chain.
Syntec Optics Holdings Inc. (NASDAQ:OPTX) is an electronic components company that deals in integrated optics and photonics components, sub-systems, and optical systems for a range of consumer end-markets, as well as defense and medical sectors.
2. Roma Green Finance Limited (NASDAQ:ROMA)
Year-to-Date Performance: 291.72%
Roma Green Finance Limited (NASDAQ:ROMA) is one of the tiny stocks that are on fire right now. On March 30, Roma Green Finance announced that its board of directors authorized a $100 million share repurchase program, effective immediately. The program, which is set to run through December 31, 2028, allows the company to buy back its Class A Ordinary Shares through various methods, including open market purchases, block trades, and privately negotiated transactions.
This move reflects the company’s discretion in managing its capital allocation and potentially addressing market valuation. The repurchases will be funded through the company’s existing cash reserves and cash flow. While the board has authorized the full amount, the company is not obligated to repurchase a specific number of shares; the actual volume and timing will depend on market conditions, stock price, and liquidity priorities.
Roma Green Finance Limited (NASDAQ:ROMA) may also implement these buybacks under Rule 10b5-1 or Rule 10b-18 plans to ensure compliance with SEC regulations regarding market manipulation and insider trading. The share repurchase program signals a step in the company’s financial strategy as it continues to support corporate clients in their transition toward sustainable business practices.
Roma Green Finance Limited (NASDAQ:ROMA) is a specialist advisory firm providing ESG, sustainability, and climate change solutions across Hong Kong and Singapore. The company offers reporting, environmental audits, and strategic advisory services to help private companies and NGOs.
1. Adlai Nortye (NASDAQ:ANL)
Year-to-Date Performance: 872.91%
Adlai Nortye (NASDAQ:ANL) is one of the tiny stocks that are on fire right now. On April 16, Adlai Nortye entered into a securities purchase agreement for a private placement equity financing/PIPE expected to yield gross proceeds of ~$150 million. The oversubscribed transaction saw significant participation from a broad group of new and existing institutional healthcare investors, including Soleus Capital, Perceptive Advisors, and Cormorant Asset Management.
The company is selling over 11.3 million American Depositary Shares/ADSs for $13.25 per share, matching its closing price on April 15. The capital infusion is earmarked to advance Adlai Nortye’s clinical-stage pipeline, specifically its RAS-targeting therapies and its proprietary next-generation ADC (antibody-drug conjugate) payload platform, RASiCA. These technologies are central to the company’s mission of transforming terminal cancers into manageable chronic conditions.
As part of the agreement, Adlai Nortye (NASDAQ:ANL) committed to filing a registration statement with the SEC to allow for the resale of the ADSs issued in the placement. High-profile firms, including Leerink Partners and Cantor, served as joint placement agents for the deal, underlining the strong market interest in the company’s specialized oncology platform.
Adlai Nortye (NASDAQ:ANL) is a global clinical-stage company developing innovative cancer therapies through R&D centers in the US and China. Its pipeline features RAS-targeting treatments, including the pan-RAS(ON) inhibitor AN9025, and next-gen immunotherapies like the tri-functional fusion protein AN8025 and oral PD-L1 inhibitor AN4005.
While we acknowledge the potential of ANL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ANL and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
